The focus of Dr. Hansmann’s laboratory is on basic mechanisms, clinically relevant biomarkers and novel therapeutic interventions in five areas:

(1) pathobiology of pulmonary vascular disease (PVD) and pulmonary hypertension (PH),

(2) right ventricular dysfunction in PVD and congenital heart disease, including new animal models and imaging modalities,

(3) the role of platelets in the pathophysiology of ductus arterious, and

(4) oxygen toxicity and bronchopulmonary dysplasia (BPD).

More specifically, Dr. Hansmann and colleagues have studied metabolic regulators, such as the transcription factor and nuclear hormone receptor, PPARgamma, adiponectin, and apolipoprotein E, in (peri)vascular cells as well as insulin resistance and dyslipidemia, as novel risk factors or modifiers of pulmonary hypertension.